CAPS and systemic lupus erythematosus: A more recent study showed that CB-CAPs (BC4d, EC4d) are more prevalent than low complement levels in patients with probable SLE [11••] and when used in a multiparameter assay panel are better than other biomarkers at predicting transition to SLE.